A potent and selective serotonin (5-HT 1A ) partial agonist with potential as a human anxiolytic drug was given in oral doses of 0, 5, 15, or 50 mg/kg/day by gavage to Sprague-Dawley rats for 6 or 12 mo. Some animals were allowed 1 mo to recover after each treatment period. The 10-fold increase in dose resulted in a 20-fold increase in drug plasma concentration due to saturable first-pass metabolism. This resulted in disproportionately higher concentrations and greater bioavailability of the 15-and 50-mg/kg/day regimens. Drug exposure was associated with decreased spontaneous activity in the 15-and 50-mg/kg rats. The activity of these rats returned to normal during the recovery period. There were significant (p < 0.05) decreases in mean body weights during the study for 50-mg/ kg males, with improvement during the recovery periods. No biologically significant effects were noted in clinical laboratory parameters. Based on organ weight increases and histopathological evaluation, drug-related effects after 6 and 12 mo of treatment were in the pituitary (both sexes) and all treated female reproductive organs. In general, these effects persisted into periods of recovery, except for pituitary hyperplasia, which was not apparent following recovery after treatment for 6 mo. After treatment for 12 mo and the following recovery, there were significant increases in adrenal weights in the 15-and 50-mg/kg/day males with no morphological correlate. There was increased pituitary hyperplasia that persisted through the recovery period in all treated groups in both sexes, but there was no increase in pituitary neoplasms. In treated females, there was also morphologic evidence of persistent diestrus (estrogenic effect) evidenced by endometrial squamous metaplasia, increased corpora lutea, vaginal mucification, and decreased uterine size. The clinical and pathological changes seen with these 2 regimens were considered exaggerated pharmacological effects of the drug on serotonin receptor-rich organs.
INTRODUCTION
Most people experience symptoms of mild anxiety from time to time, usually associated with tension or stress-associated situations such as public speaking, dental, or surgical procedures. Pathologic anxiety usually refers to the episodic or chronic experiences of anxiety severe enough to interfere with normal living. Generalized anxiety is most often treated with benzodiazepines such as chlordiazepoxide, diazepam, and oxazepam (3, 7) . Alcohol is probably the most common self-medication for anxiety. While the benzodiazepines represent significant improvements over earlier treatments, some disadvantages remain. These disadvantag-es include sedation, habituation, abuse potential, withdrawal hyperexcitability, and prominent interaction with alcohol and other sedative hypnotics (4) . Clinically, effective anxiolytics with efficacy equal to or improved over the benzodiazepines but lacking sedative and addictive properties are needed for the treatmenl of humans. The pharmacological premise for beneficial action in a novel class of compounds under clinica' development is the assumption that reduction of serotonin transmission will result in clinical anxiolytic act tion. This class is comprised of the azaspirodecanediones, of which buspirone (currently marketed by Bristol-Squibb) is the prototype, is effective in relief of anxiety, and is free from disadvantages of the benzodiazepines and suitably safe in humans.
A serotonin (5-HTI,) partial agonist under development as a human anxiolytic drug was studied in a 4-wk oral toxicity study in rats; doses of 10 mg/kg/day and above caused decreased spontaneous activity. Males given 300 mg/kg/day had significantly (p < 0.05) decreased food consumption and body weights and the 30-, 100-, and 300mg/kg/day females had significantly (p < 0.05) increased liver weights. There were no drug effects after 4 wk of treatment withdrawal (unpublished data). The purpose of this reported study was to determine the drug's toxicity following oral administration to rats for 1 yr. one,methane-sulfonate was verified by Analytical Chemistry, Indianapolis Research Center (Fig. 1 ). It is a racemate drug with S(+) and S(-) components. The S(-) component has slightly greater affinity for 5-HTIA receptors. Dose solutions of test material were prepared daily in chilled distilled water to ensure suitability for the study. Animals Experimental Design. During a 13-day acclimation period, rats were randomly assigned to a control and 3 treatment groups of 35 rats/sex:
METHODS
~.
, Clinical Observations. Rats were observed daily for abnormalities in physical appearance and behavior. Individual food consumption and body weights were recorded weekly the first 14 wk, once every 2 wk for weeks 15-53, and weekly for recovery rats. Body weights of fasted rats were recorded at scheduled necropsies. Clinical Laboratory Studies. Cardiac blood samples were collected from fasted rats at scheduled necropsies. Hematologic parameters included hematocrit, hemoglobin, total red blood cells, white blood cells and platelet counts, erythrocyte indices, and differential white blood cell counts. Clinical chemistry parameters included blood urea nitrogen, glucose, alanine aminotransferase, aspar-tate aminotransferase, alkaline phosphatase, total protein, albumin, globulin, A/G ratio, cholesterol, triglyceride, calcium, total bilirubin, sodium, potassium, chloride, and phosphate.
Urine was collected from the urinary bladder at necropsy and examined for gross appearance, pH, specific gravity, glucose, ketones, blood, protein, urobilinogen, and bilirubin.
Pharmacokinetic Studies. Six rats of each sex dosed in parallel with those of the toxicity study were sacrificed by exsanguination while under methoxyflurane anesthesia 2 hr after dosing on day 24 to collect plasma samples for drug concentration measurements. Blood was collected in heparinized glass tubes, cooled briefly in ice water, and then centrifuged. Plasma was removed, acidified by adding 2 N HCI, and stored at -20°C. Samples were analyzed for drug by 1 of 2 validated methods: (a) samples in the 25-2,000-ng/ml range were analyzed by a high-pressure liquid chromatography method with ultraviolet detection (D. K Pathology Studies. All rats were necropsied. Brain, heart, liver, kidneys, adrenals, pituitary, gonads, uterus, and spleen were weighed at the scheduled necropsies.
Routine tissues were collected in 10% buffered formalin, and hematoxylin and eosin preparations were made for light microscopic examination.
RESULTS AND DISCUSSION

Clinical Observations
There were no drug-related deaths in either sex. Both males and females given ? 15 mg/kg/day had decreased activity, which was somewhat time and dose-dependent, as follows: (a) During the first treatment month there was decreased activity that lasted more than 6 but less than 24 hr, and (b) between 2 and 12 mo decreased activity lasted about 1 hr at 15 mg/kg/day and 2 hr at 50 mg/kg/ day. The drug of this report, based on pharmacological TABLE IV-Summary of histopathologic observations-6-mo necropsy.
One gland missing, b Two tissues missing. screening studies, is believed to reduce serotonin (5HT) transmission in 2 ways: (a) by acting as an agonist at the presynaptic 5-HT1A autoreceptor, it would reduce 5-HT cell firing; and (b) by acting as an antagonist at the postsynaptic 5-HT1A receptor, it would reduce the effects of 5-HT released into the synapse.
Body Weight and Food Consumption
Mean body weights (Fig. 2) were reduced between 2 and 12 mo for 50-mg/kg males in concert with variable reductions in mean food consumption for 2-5 mo. For most of the study, there were increased group mean body weights for treated females. During the period of 0-3 mo group mean food consumption (Fig. 2 ) increased for all female treatment groups. Body weights and food consumption in both sexes generally returned to normal during a 1-mo recovery period after either 6 or 12 mo of treatment.
Clinical Laboratory Studies
There were no biologically or toxicologically significant alterations of hematology, serum chemistry, or urinalysis parameters associated with treatment.
Pharmacokinetic Studies
Steady-state plasma concentrations of drug 2 hr after the 24th dose ranged from 9 to 616 ng/ml. There were greater-than-proportional increases in geometric mean plasma concentrations in this time-frame as dose increased from 5 to 50 mg/kg/day. This 10-fold increase in dose resulted in a 20-fold increase in drug plasma concentration. Previous studies in the rat indicated saturable first-pass metabolism (G. H. Hurst, J. A. Vigil, D. K. Satonin, D. S. Risley, and D. R. Shepard; 1988, personal communication) occurred and was responsible for the disproportionately higher concentrations and greater bioavailability of the 15-and 50-mg/kg/day regimens. 
Pathology Studies
Necropsy revealed no gross effects associated with treatment except for increased ovarian and reduced uterine weights in 15-50-mg/kg/day females beginning at 6 mo plus 1 mo of recovery (Table I) (Table II) . Following 12 mo of treatment and a 1-mo recovery period, there was persistence of these organ weight changes (Table III) . While there was no increase in pituitary gland weights compared to controls that had normal morphology (Fig. 3 ), a treat- (Tables IV-VII ) at 6 and 12 mo. The no-effect level was 5 mg/kg/ day in males at the 6-and 12-mo periods while 5-50mg/kg/day females were affected. Both sexes appeared to recover upon examination of pituitary glands at the 6-mo recovery period, whereas 15-50-mg/kg/day males and females were affected at the 12-mo recovery period. In contrast to normal control ovaries (Tables I-VII and Fig.  6 ), there were increases in ovarian weights (Tables I-III), and increased presence of corpora lutea (Tables IV, VI, VII and Fig. 7 ) occurred in all female treatment groups consistent with an estrogenic effect of the drug. There were small morphologic differences in the uterus between control (Fig. 8 ) and treated (Fig. 9 ) females. Treated females had thickened mucosa with less submucosal stroma in contrast to controls. Both were morphologically normal. Vaginal changes with treatment included mucosal thickening and mucification (Tables IV-VII) consistent with diestrus in females of all treatment groups.
The administration of this drug in humans elicited increased plasma concentrations of adrenocorticotrophic hormone, prolactin, and growth hormone (Q. Mekki, 1990, personal communication), suggestive of increased pituitary activity. Although plasma concentrations of these hormones were not measured in rats of this study, pituitary chromophobe cell hyperplasia observed in both sexes, light microscopically, may be related to the effects in humans. Furthermore, if the reproductive system changes noted in rats were secondary to increased prolactin secretion, these effects may not occur in women because prolactin does not have luteotrophic effects in humans (6) . Excessive stimulation of serotonin receptors known to be present in the brain, hypothalamus, and peripheral organs including the ovaries and uterus (1, 2, 5, 8) was considered the cause of treatment-related effects in the pituitary, ovaries, vagina, and uterus.
SUMMARY
In this 1-yr toxicity study of a novel serotonin 5-HT1A antagonist in Sprague-Dawley rats, doses of 0, 5, 15, or 50 mg/kg/day (10-100 X human dose) were employed. There was decreased spontaneous activity in both sexes at 15 and 50 mg/kg/day that appeared to be both timeand dose-dependent. Decreased mean body weight occurred only in 50-mg/kg/day males whereas 5-, 15-, and 50-mg/kg females had increased mean body weights. In both sexes there was a small increase in pituitary chromophobe cell hyperplasia at 6 mo that became more pronounced by 12 mo. There were increased ovarian weights and number of corpora lutea in all female treatment groups. All treated females also had decreased uterine size and weight. There was also vaginal mucosal thickening and mucification consistent with diestrus in all female treatment groups.
